Previously we have shown that treatment with the dual ETA/ETB antagonist tezosentan attenuates the decrease in total renal blood flow and renal cortical microcirculation caused by endotoxemia [16]. This evidence concerns the gene EDNRB and serum lipopolysaccharide activity.